spacer
home > ict > Winter 2018
PUBLICATIONS

International Clinical Trials

ict
Winter 2018

   
Text
PDF
bullet
REGULATORY
The Great Data Protection Regulation

Protected and Prepared


To protect personal data, the industry must adapt to a new set of practices implemented by the Great Protection Regulation, as explained Mike Novotny and Nick O’Brien at Medrio.
 
view
download pdf
Risk Management Methods

Preventable Problems

Sudeep Pattnaik at ThoughtSphere examines risk-based monitoring methods, suggesting that they are becoming the newly recognised industry standard.
 
view
download pdf
bullet
Clinical Trial Management
Central Nervous System Trials

Clinical Complexities

Clinical trials for the central nervous system are becoming more intricate and expensive. Tom Zoda at Syneos Health discusses the challenges that must be overcome in this sector.
 
view
download pdf
Patient Engagement and Compliance

Perfect Platform


Following the guidelines set out by the Washington University DIAN-TU platform, Graham Wylie at MRN states that these standards are good for current practices, noting the ways it affects Alzheimer’s research.
 
view
download pdf
CNS Drug Development

Clinical Acceleration

Dr Kemi Olugemo
at PAREXEL highlights how the need for an increase in clinical trials is vital as diseases caused by the central nervous system accelerate.

 
view
download pdf
Clinical Reference Models
Bridging the Divide

Using electronic document management and trial master file reference models can offer assistance when managing the growing amount of regulatory
submissions, explains Patricia Santos-Serrao at MasterControl.
 
view
download pdf
bullet
eCLINICAL
Digitising Patient-Reported Outcomes

PROMs in Practise


By using digital patient-reported outcome measures, healthcare organisations are now able to measure patient outcomes with greater accuracy. Dr Tim Williams at My Clinical Outcomes details the ways this helps care and practices.

 
view
download pdf
bullet
PREVIEW
Uniting professionals across life sciences, DIA Europe 2018 will be held this year in Basel, Switzerland, on 17-19 April.
 
view
download pdf
bullet
data management & statistical analysis
Mitigating Data Risks
 
Promoting Patterns
 
Poor data management is negatively affecting adverse event and endpoint adjudication in clinical trials. Abraham Gutman at AG Mednet believes developing and validating control and event patterns may be the solution.

 
view
download pdf

Patient Recruitment and Retention
Patient Retention
 
Dodging Delays
 
Martin Collyer
at Bioclinica talks about the new methods that must be taken to reduce patient-loss during the follow-up period.

 
view
download pdf
Behavioural Economics

Assessing Attitudes
 
Creating and maintaining patient engagement has been researched in numerous ways. One of those approaches is Behaviour Economics, which Keith Meadows at DHP Research & Consultancy explores.

 
view
download pdf
Patient Participation
 
Changing Ways
 
Kurt Mussina at Frenova Renal Research points out that recruitment rates can be improved through patient-centricity, thereby minimising administrative and practical difficulties.
 
view
download pdf
Patient Centricity

Promising Participation


Lea Studer at SCORR Marketing examines the role of patient centricity within trials, suggesting that the process could be improved by keeping patients informed, seeking their input, and analysing their desires
 
view
download pdf
Patient-Reported Outcomes

Collective Communication


The collection of patient-reported outcomes in clinical trials has become more commonplace; however, Dr Jenny Retzler at York Health Economics Consortium explores the problems that may be countered though early engagement.
 
view
download pdf
bullet
Digital Advances
mHealth Developments

A Valued Perspective

The acceleration of R&D is coming to fruition thanks to the implementation of mHealth technologies. David Blackman at PPD hopes it will improve practices and explore new markets.
 
view
download pdf
   
spacer


Published quarterly in
February, May,
August, and November

News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement